Ohkuchi, Akihide
Saito, Shigeru
Yamamoto, Tatsuo
Minakami, Hisanori
Masuyama, Hisashi
Kumasawa, Keiichi
Yoshimatsu, Jun
Nagamatsu, Takeshi
Dietl, Angela
Grill, Sonja
Hund, Martin
Article History
Received: 17 July 2020
Revised: 17 November 2020
Accepted: 9 December 2020
First Online: 17 March 2021
Compliance with ethical standards
:
: KK, HM, HM, TN, and JY report no competing interests. AO, TY, and SS received fees from Roche Diagnostics Ltd during the conduct of the study. AD and SG are employees of Roche Diagnostics Ltd. MH is an employee of Roche Diagnostics Ltd and holds stock in F. Hoffmann-La Roche. MH also reports being an inventor of patents related to the sFlt-1/PlGF or endoglin/PlGF ratio to rule out the onset of preeclampsia in pregnant women within a certain time period (PCT/EP2013/063115) and the dynamics of the sFlt-1 or endoglin/PlGF ratio as an indicator for imminent preeclampsia and HELLP syndrome (PCT/EP2012/072157).